Literature DB >> 25311966

Radiation emission from patients treated with holmium-166 radioembolization.

Jip F Prince1, Maarten L J Smits2, Gerard C Krijger2, Bernard A Zonnenberg2, Maurice A A J van den Bosch2, Johannes F W Nijsen2, Marnix G E H Lam2.   

Abstract

PURPOSE: To assess the radiation exposure to individuals coming from patients after treatment with holmium-166 ((166)Ho) microspheres.
MATERIALS AND METHODS: Holmium-166 radioembolization (RE) with escalating whole-liver doses of 20 Gy, 40 Gy, 60 Gy, and 80 Gy was administered to 15 patients. Exposure rates (μSv/h) from patients were measured at 1.0 m distance from a lateral and frontal position at 0, 3, 6, 24, and 48 hours after infusion. The total effective dose equivalent (TEDE) to a maximally exposed contact was calculated in accordance with guidelines of the U.S. Nuclear Regulatory Commission (NRC). Results were extrapolated to a whole-liver dose of 60 Gy used in future treatments.
RESULTS: The median exposure rate at discharge, 48 hours after infusion, measured from a lateral position was 26 μSv/h (range, 7-45 μSv/h). Extrapolated to a whole-liver dose of 60 Gy, none of the exposure rates for the NRC contact scenario, at any time, frontal or lateral, would lead to a TEDE > 5 mSv; all patients may be released directly after treatment. Release after 6 hours is possible without contact restrictions for patients who received up to 7 GBq.
CONCLUSIONS: The TEDE to a contact of patients treated with (166)Ho RE would not exceed the NRC limit of 5 mSv. Contact restrictions 6 hours after treatment are unnecessary for infused activities < 7 GBq.
Copyright © 2014 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25311966     DOI: 10.1016/j.jvir.2014.09.003

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  Biodegradable seeds of holmium don't change neurological function after implant in brain of rats.

Authors:  Mirla Fiuza Diniz; Diogo Milioli Ferreira; Wanderson Geraldo de Lima; Maria Lucia Pedrosa; Marcelo Eustáquio Silva; Stanley de Almeida Araujo; Kinulpe Honorato Sampaio; Tarcisio Passos Ribeiro de Campos; Savio Lana Siqueira
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-11

2.  166Ho microsphere scout dose for more accurate radioembolization treatment planning.

Authors:  C Chiesa; M Maccauro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04       Impact factor: 9.236

3.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  M Weber; M Lam; C Chiesa; M Konijnenberg; M Cremonesi; P Flamen; S Gnesin; L Bodei; T Kracmerova; M Luster; E Garin; K Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-11       Impact factor: 9.236

Review 4.  Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres.

Authors:  C Bouvry; X Palard; J Edeline; V Ardisson; P Loyer; E Garin; N Lepareur
Journal:  Biomed Res Int       Date:  2018-12-31       Impact factor: 3.246

Review 5.  The various therapeutic applications of the medical isotope holmium-166: a narrative review.

Authors:  Nienke J M Klaassen; Mark J Arntz; Alexandra Gil Arranja; Joey Roosen; J Frank W Nijsen
Journal:  EJNMMI Radiopharm Chem       Date:  2019-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.